Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

High seroprevalence of SARS-CoV-2 antibodies among people living in precarious situations in Ile de France

Thomas Roederer, Bastien Mollo, Charline Vincent, Birgit Nikolay, Augusto Llosa, Robin Nesbitt, Jessica Vanhomwegen, Thierry Rose, François Anna, Corinne Torre, Emilie Fourrey, Erica Simons, Sophie Goyard, Yves Janin, Pierre Charneau, Oxana Vratskikh, Anneliese Coury, Stefan Vanel, Pierre Mendiharat, Klaudia Porten, William Hennequin, Clair Mills, Francisco Luquero
doi: https://doi.org/10.1101/2020.10.07.20207795
Thomas Roederer
1Epicentre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thomas.roederer@epicentre.msf.org
Bastien Mollo
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charline Vincent
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgit Nikolay
1Epicentre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Augusto Llosa
1Epicentre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Nesbitt
1Epicentre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Vanhomwegen
3Environment and Infectious Risks Research and Expertise Unit, Global Health Department, Institut Pasteur, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Rose
4Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, INSERM 1221, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Anna
5Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France
6Theravectys, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corinne Torre
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilie Fourrey
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica Simons
1Epicentre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Goyard
4Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, INSERM 1221, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Janin
7Unit of Chemistry and Biocatalysis, Institut Pasteur, UMR 3523 CNRS, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Charneau
5Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France
6Theravectys, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oxana Vratskikh
3Environment and Infectious Risks Research and Expertise Unit, Global Health Department, Institut Pasteur, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anneliese Coury
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Vanel
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Mendiharat
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaudia Porten
1Epicentre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Hennequin
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clair Mills
2Médecins Sans Frontières, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Luquero
1Epicentre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background A nationwide lockdown was implemented in France on 17 March 2020 to control the COVID-19 pandemic. People living in precarious conditions were relocated by the authorities to emergency shelters, hotels and large venues. Médecins sans Frontières (MSF) then intervened to provide medical care in several of these locations in Paris and in Seine-Saint-Denis, one of its suburbs, between March and June 2020. A seroprevalence survey was conducted to assess the level of exposure to COVID-19 among the population living in the sites. To our knowledge, this is the first assessment of the impact of the pandemic on populations living in insecure conditions in Europe.

Methods We conducted a cross-sectional seroprevalence study in the food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis, to determine the extent of COVID-19 exposure as determined by SARS-CoV2 antibody seropositivity. The detection of SARS-COV2 antibodies in serum was performed at the Institut Pasteur of Paris using two LuLISA (Luciferase-Linked Immunosorbent Assay) assays and a Pseudo Neutralization Test. A questionnaire covering sociodemographic characteristics, living conditions, adherence to sanitary recommendations and symptom manifestations was also completed. We describe here the seroprevalence site by site and identify the risk factors for seropositivity using a multivariable logistic regression model with site random effects. We also investigated associations between seropositivity and symptoms eventually reported.

Findings Overall, 426/818 individuals tested positive in the 14 sites investigated. Seroprevalence varied significantly with the type of site (chi2 p<0.001). It was highest at 88.7% (95%CI 81.8-93.2) among individuals living in workers’ residences, followed by 50.5% (95%CI 46.3-54.7) in emergency shelters and 27.8 % (95%CI 20.8-35.7) among individuals recruited from the food distribution sites. Seroprevalence also varied significantly between sites of the same type. Among other risk factors, the odds for seropositivity were higher among individuals living in crowded sites (medium: adj. OR 2.7, 95%CI 1.5-5.1, p=0.001; high: adj. OR 3.4, 95%CI 1.7-6.9, p<0.001) compared with individuals from low crowding sites and among those who reported transit accommodation in a gymnasium before the lockdown (adj. OR 3.1, 95%CI 1.2-8.1, p=0.023). More than two-thirds of the seropositive individuals (68.3%; 95%CI 64.2-72.2) did not report any symptoms during the recall period.

Interpretation The results demonstrate rather high exposure to SARS-COV-2 with important variations between study sites. Living in crowded conditions was identified as the most important explanatory factor for differences in levels of exposure. This study describes the key factors which determine the risk of exposure and illustrates the importance of identifying populations at high risk of exposure in order to orient and adapt prevention and control strategies to their specific needs.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Study was registered in France only, it is not a clinical trial, but an epidemiological survey in population.

Funding Statement

No external funding was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This protocol was approved by the MSF ethics review board on 18 June 2020, reference number 2044) and by the Comite de Protection des Personnes (CPP), Ile de France, Paris XI, approved 19 June 2020 (reference number 20050-62628).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Databases used for the analyses are available upon request to the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 09, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
High seroprevalence of SARS-CoV-2 antibodies among people living in precarious situations in Ile de France
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
High seroprevalence of SARS-CoV-2 antibodies among people living in precarious situations in Ile de France
Thomas Roederer, Bastien Mollo, Charline Vincent, Birgit Nikolay, Augusto Llosa, Robin Nesbitt, Jessica Vanhomwegen, Thierry Rose, François Anna, Corinne Torre, Emilie Fourrey, Erica Simons, Sophie Goyard, Yves Janin, Pierre Charneau, Oxana Vratskikh, Anneliese Coury, Stefan Vanel, Pierre Mendiharat, Klaudia Porten, William Hennequin, Clair Mills, Francisco Luquero
medRxiv 2020.10.07.20207795; doi: https://doi.org/10.1101/2020.10.07.20207795
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
High seroprevalence of SARS-CoV-2 antibodies among people living in precarious situations in Ile de France
Thomas Roederer, Bastien Mollo, Charline Vincent, Birgit Nikolay, Augusto Llosa, Robin Nesbitt, Jessica Vanhomwegen, Thierry Rose, François Anna, Corinne Torre, Emilie Fourrey, Erica Simons, Sophie Goyard, Yves Janin, Pierre Charneau, Oxana Vratskikh, Anneliese Coury, Stefan Vanel, Pierre Mendiharat, Klaudia Porten, William Hennequin, Clair Mills, Francisco Luquero
medRxiv 2020.10.07.20207795; doi: https://doi.org/10.1101/2020.10.07.20207795

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (47)
  • Cardiovascular Medicine (416)
  • Dentistry and Oral Medicine (70)
  • Dermatology (49)
  • Emergency Medicine (146)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4875)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (678)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (633)
  • Health Policy (322)
  • Health Systems and Quality Improvement (208)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5362)
  • Intensive Care and Critical Care Medicine (332)
  • Medical Education (94)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (690)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (127)
  • Occupational and Environmental Health (209)
  • Oncology (443)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (17)
  • Pathology (130)
  • Pediatrics (196)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (782)
  • Public and Global Health (1823)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)